Pin-Xian Xu, PhD
- PROFESSOR | Genetics and Genomic Sciences
- PROFESSOR | Cell, Developmental & Regenerative Biology
Research Topics:
Auditory, Developmental Biology, Epigenetics, Gene Regulation, Genetics, Genomics, Human Genetics and Genetic Disorders, Inner Ear, Kidney, Knockout Mice, Neuroscience, Organogenesis, Protein Phosphatases, RegenerationMulti-Disciplinary Training Areas
Development, Regeneration, and Stem Cells [DRS], Genetics and Data Science [GDS], Neuroscience [NEU]Education
PhD, The Graduate University for Advanced Studies, Japan
Postdoctoral fellow, Harvard Medical School/Brigham & Women's Hospital
-
2007
Member -
2000
Research Award -
1999
Recipient of 50th Anniversary Program for Scholars in Medicine Fellowship -
1997
Individual National Research Service Award
Pin-Xian Xu’s laboratory studies regulatory networks that drive organogenesis. In particular, our lab is interested in the general question of how cell diversity in our body is created. A major focus of our research is auditory and renal development and maintenance, where we seek to identify the pathways by which EYA1 drives a small group of progenitor cells to become functional sensory neurons and hair cells in the inner ear or nephrons in the kidney. For more detailed information, please consult our lab website.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Xu did not report having any of the following types of financial relationships with industry during 2019 and/or 2020: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.